Please wait while we load the requested 10-K report or click the link below:
NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014
– Gattex® delivers strong performance with 2013 sales of $31.8 million –
– Global Short Bowel Syndrome franchise expected to grow by more than 250% in 2014 --
– Natpara® BLA review underway with PDUFA date of October 24 –
– Conference call today at 5:00 PM ET –
BEDMINSTER, N.J.--(BUSINESS WIRE)--February 18, 2014--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.
NPS reported net global product sales of $15.3 million for the fourth quarter of 2013 and $31.8 million for the full year. These results are at the high end of the company’s 2013 guidance of $28 to $32 million in net sales. In February 2013, NPS launched and initiated sales of its first commercial product Gattex® (teduglutide [rDNA origin]) for injection in the US for the treatment of patients with adult Short Bowel Syndrome (SBS) who are dependent on parenteral support. Teduglutide is also approved in the European Union (EU) under the trade name Revestive® and is expected to launch in certain countries in 2014.
“2013 was a transformative year in which we successfully established NPS as a global commercial rare disease company with the US launch of Gattex and the regaining of the ex-US rights to our two products,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “Looking forward to 2014, we will continue to execute our growth strategy to build a premier global orphan drug business. Our key initiatives are growing Gattex sales in the US, launching Revestive in certain ex-US markets, securing US approval of Natpara for hypoparathyroidism, and building a global pipeline of innovative, ‘first-in’ or ‘best-in’ rare disease therapeutics.”
The following information was filed by Nps Pharmaceuticals Inc (NPSP) on Tuesday, February 18, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Nps Pharmaceuticals Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Nps Pharmaceuticals Inc.